Skip to main content

XORTX Therapeutics Inc.

corporate_fare Company Profile

XORTX Therapeutics Inc.

XRTX·NASDAQ·Life Sciences·CIK 0001729214

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing treatments for diseases linked to high uric acid levels in Canada. The company is developing several therapies: XRx-026, which is in Phase III clinical trials for treating gout; XRx-008, currently in Phase II for autosomal dominant polycystic kidney disease; and XRx-101, also in Phase II, for acute kidney injury resulting from respiratory virus infections, including sepsis and coronavirus. Additionally, XRX-225 is in the preclinical stage for treating type 2 diabetic nephropathy. XORTX Therapeutics Inc. also has a program called VB4-P5, which aims to treat and prevent kidney fibrosis. The company operates from Calgary, Canada.

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors XRTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • XORTX Therapeutics Announces Pioneering Research Validating Gout & Kidney Disease Therapeutic Strategy

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$2.66M
Diluted EPS
-$0.56
Op. Cash Flow
-$2.77M
Cash & Equivalents
$864.51K
Debt / Equity
0.00×
Shares Outstanding
6.96M sh
Source: 20-F · filed 2026-03-20 · accession 0001104659-26-032775

Insider Transactions

XRTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$2.19 +0.04% today
52-week range · as of 2026-08-17 $1.73 – $7.05
Market cap
$3.72M
Volume
7.6K (0.6× avg)
3-mo avg 12.8K
Live data · 2026-08-19 08:03 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed XRTX - Filings & News (Page 2)

XRTX
Jan 02, 2026, 2:38 PM EST
Filing Type: 6-K
Importance Score:
7
XORTX Therapeutics Announces Pioneering Research Validating Gout & Kidney Disease Therapeutic Strategy
Price at Filing: $0.590
Real-time Price: $2.19 info
Change: Reverse Stock Split info
Market Cap: $3.719M info
Sentiment: Positive
View Wiseek Article